<DOC>
	<DOCNO>NCT02289456</DOCNO>
	<brief_summary>4 cycle induction treatment nab-paclitaxel carboplatin follow nab-paclitaxel monotherapy subject progression free end 4 cycle .</brief_summary>
	<brief_title>Phase II Safety Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed Nab-Paclitaxel First Line Treatment NSCLC Subjects With ECOG PS 2</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>General Demographics 1 . Age ≥ 18 year age time sign Informed Consent Form . 2 . Understand voluntarily provide write consent Informed Consent Form prior conduct study related assessments/procedures . 3 . Able adhere study visit schedule protocol requirement . Disease Specific 4 . Histologically cytologically confirm Stage IIIB IV NonSmall Cell Lung Cancer . 5 . Radiographically document measurable disease study entry per response evaluation criterion solid tumour ( RECIST ) v1.1 . 6 . No prior anticancer therapy treatment metastatic disease time sign ICF . Adjuvant treatment permit provide cytotoxic chemotherapy complete 12 month prior sign ICF without disease recurrence . 7 . Absolute neutrophil count ( ANC ) ≥ 1500 cells/mm3 . 8 . Platelets ≥ 100,000 cells/mm3 . 9 . Hemoglobin ( Hgb ) ≥ 9 g/dL . 10 . Aspartate transaminase ( AST/serum glutamic oxaloacetic transaminase [ SGOT ] ) , alanine transaminase ( ALT/serum glutamic pyruvic transaminase [ SGPT ] ) ≤ 2.5 × upper limit normal range ( ULN ) ≤ 5.0 × ULN liver metastasis . 11 . Total bilirubin ≤ 1.5 × ULN except case Gilbert 's disease liver metastases . 12 . Serum creatinine ≤ 1.5 x ULN , calculate creatinine clearance ≥ 40 mL/min ( renal impairment suspect 24hour urine collection measurement require ) . 13 . Eastern Cooperative Oncology Group Performance Status 2 . 14 . Females childbearing potential [ define sexually mature woman ( 1 ) undergone hysterectomy ( surgical removal uterus ) bilateral oophorectomy ( surgical removal ovary ) ( 2 ) naturally postmenopausal least 24 consecutive month ( ie , menses time precede 24 consecutive month ) ] must : 1 . Have negative pregnancy test Beta Human Chorionic Gonaditrophin ( ßhCG ) verify study doctor within 72 hour prior start study therapy . 2 . You must commit complete abstinence heterosexual contact , agree use medical doctorapproved contraception throughout study without interruption ; receive study medication longer period require local regulation . Male subject must : 3. practice true abstinence* agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption least 6 month follow study drug discontinuation , even undergone successful vasectomy . The presence follow exclude subject enrollment : 1 . Evidence active brain metastasis , include leptomeningeal involvement ( prior evidence brain metastasis permit treated stable therapy least 21days prior sign ICF ) . MRI brain ( CT scan w/contrast ) prefer diagnosis . 2 . History leptomeningeal disease . 3 . Only evidence disease nonmeasurable . 4 . Preexisting peripheral neuropathy Grade 2 , 3 , 4 ( per Criteria Adverse Events ( CTCAE ) v4.0 ) . 5 . Subject receive radiotherapy ≤ 4 week limited field radiation palliation ≤ 2 week prior start investigational product ( IP ) , and/or ≥ 30 % bone marrow irradiate . Prior radiation therapy target lesion permit clear progression lesion since radiation complete . 6 . Venous thromboembolism within 1 month prior sign ICF . 7 . Current congestive heart failure ( New York Heart Association Class IIIV ) . 8 . History follow within 6 month prior first administration investigational product : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , New York Heart Association ( NYHA ) Class IIIIV heart failure , uncontrolled hypertension , clinically significant cardiac dysrhythmia clinically significant ECG abnormality , cerebrovascular accident , transient ischemic attack , seizure disorder . 9 . Subject know infection hepatitis B C , history human immunodeficiency virus ( HIV ) infection , subject receive immunosuppressive myelosuppressive medication would opinion investigator , increase risk serious neutropenic complication . 10 . Subject active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy , define ongoing signs/symptoms related infection without improvement despite appropriate antibiotic , antiviral therapy , and/or treatment . 11 . History interstitial lung disease , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis . 12 . Treatment investigational product within 28 day prior sign ICF . 13 . History suspect allergy nabpaclitaxel , carboplatin human albumin platinumbased therapy . 14 . Currently enrol clinical protocol investigational trial involve administration experimental therapy and/or therapeutic device . 15 . Any clinically significant medical condition , psychiatric illness , and/or organ dysfunction interfere administration therapy accord protocol , view investigator , preclude combination chemotherapy . 16 . Subject malignancy within 5 year prior sign ICF . Exceptions include follow : squamous cell carcinoma skin , insitu carcinoma cervix , uteri , nonmelanomatous skin cancer , carcinoma situ breast , incidental histological finding prostate cancer ( Tumor , node metastasis ( TNM ) stage T1a T1b ) . All treatment complete 6 month prior sign ICF . 17 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 18 . Any medical condition confounds ability interpret data study . This include subject know psychiatric disorder . 19 . Pregnant breastfeeding female . 20 . Subjects ECOG PS 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase II , LOCALLY ADVANCED OR METASTATIC NON SMALL</keyword>
	<keyword>CELL LUNG CANCER ( NSCLC ) AND AN</keyword>
	<keyword>EASTERN COOPERATIVE ONCOLOGY GROUP</keyword>
	<keyword>PERFORMANCE STATUS OF 2</keyword>
	<keyword>( ABOUND.PS2 )</keyword>
	<keyword>LOCALLY ADVANCED OR METASTATIC NON SMALL</keyword>
	<keyword>CELL LUNG CANCER ( NSCLC ) SUBJECTS THAT AE NOT CANDIDATES FOR RADIATION OR CURATIVE SURGERY</keyword>
</DOC>